磺胺过敏和眼部弓形虫病的替代治疗。

Francisco Calleja Casado, Antonio Duch Samper
{"title":"磺胺过敏和眼部弓形虫病的替代治疗。","authors":"Francisco Calleja Casado, Antonio Duch Samper","doi":"10.22336/rjo.2025.25","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To summarize current knowledge on the clinical features, diagnosis, and treatment of ocular toxoplasmosis, with emphasis on alternatives for sulfonamide-allergic patients.</p><p><strong>Materials and methods: </strong>A comprehensive PubMed search (1908-2021) was conducted using terms like <i>Toxoplasma gondii</i>, ocular toxoplasmosis, posterior uveitis, and retinochoroiditis. Priority was given to studies published after 2000, particularly those from 2010 onwards. Google Scholar, as well as English and Spanish sources, were also utilized.</p><p><strong>Results: </strong>Ocular toxoplasmosis is the most common infectious form of posterior uveitis worldwide, typically presenting as necrotizing retinochoroiditis with associated vitreomacular adhesion and vitritis. Diagnosis is mainly clinical, supported by serology (IgG/IgM) and PCR of intraocular fluids when needed. Standard treatment includes systemic antiparasitic agents (e.g., pyrimethamine with sulfadiazine or trimethoprim-sulfamethoxazole) plus corticosteroids. In patients with sulfonamide allergies, alternatives such as pyrimethamine with clindamycin or azithromycin, or intravitreal clindamycin with dexamethasone, are effective. Recent studies show comparable outcomes with these regimens. Prompt treatment of active disease helps reduce retinal damage.</p><p><strong>Discussion: </strong>Recent evidence supports the efficacy and safety of non-sulfonamide regimens and intravitreal therapies in managing ocular toxoplasmosis. These options are particularly valuable for patients with contraindications to standard treatments. Advances in imaging and molecular diagnostics have also enhanced early recognition and tailored management of the disease, contributing to improved visual outcomes.</p><p><strong>Conclusion: </strong>Advances in diagnostic tools (PCR, intraocular antibody detection) and alternative therapies have improved outcomes in ocular toxoplasmosis, including in patients who are intolerant to sulfonamides. Clindamycin-based or intravitreal approaches offer effective, safe options. Further research is needed to refine treatment protocols, prevent recurrences, and clarify disease pathogenesis.</p>","PeriodicalId":94355,"journal":{"name":"Romanian journal of ophthalmology","volume":"69 2","pages":"147-157"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277979/pdf/","citationCount":"0","resultStr":"{\"title\":\"Sulfonamide Allergy and Alternative Treatments in Ocular Toxoplasmosis.\",\"authors\":\"Francisco Calleja Casado, Antonio Duch Samper\",\"doi\":\"10.22336/rjo.2025.25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To summarize current knowledge on the clinical features, diagnosis, and treatment of ocular toxoplasmosis, with emphasis on alternatives for sulfonamide-allergic patients.</p><p><strong>Materials and methods: </strong>A comprehensive PubMed search (1908-2021) was conducted using terms like <i>Toxoplasma gondii</i>, ocular toxoplasmosis, posterior uveitis, and retinochoroiditis. Priority was given to studies published after 2000, particularly those from 2010 onwards. Google Scholar, as well as English and Spanish sources, were also utilized.</p><p><strong>Results: </strong>Ocular toxoplasmosis is the most common infectious form of posterior uveitis worldwide, typically presenting as necrotizing retinochoroiditis with associated vitreomacular adhesion and vitritis. Diagnosis is mainly clinical, supported by serology (IgG/IgM) and PCR of intraocular fluids when needed. Standard treatment includes systemic antiparasitic agents (e.g., pyrimethamine with sulfadiazine or trimethoprim-sulfamethoxazole) plus corticosteroids. In patients with sulfonamide allergies, alternatives such as pyrimethamine with clindamycin or azithromycin, or intravitreal clindamycin with dexamethasone, are effective. Recent studies show comparable outcomes with these regimens. Prompt treatment of active disease helps reduce retinal damage.</p><p><strong>Discussion: </strong>Recent evidence supports the efficacy and safety of non-sulfonamide regimens and intravitreal therapies in managing ocular toxoplasmosis. These options are particularly valuable for patients with contraindications to standard treatments. Advances in imaging and molecular diagnostics have also enhanced early recognition and tailored management of the disease, contributing to improved visual outcomes.</p><p><strong>Conclusion: </strong>Advances in diagnostic tools (PCR, intraocular antibody detection) and alternative therapies have improved outcomes in ocular toxoplasmosis, including in patients who are intolerant to sulfonamides. Clindamycin-based or intravitreal approaches offer effective, safe options. Further research is needed to refine treatment protocols, prevent recurrences, and clarify disease pathogenesis.</p>\",\"PeriodicalId\":94355,\"journal\":{\"name\":\"Romanian journal of ophthalmology\",\"volume\":\"69 2\",\"pages\":\"147-157\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277979/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Romanian journal of ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22336/rjo.2025.25\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Romanian journal of ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22336/rjo.2025.25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:总结目前关于眼弓形虫病的临床特征、诊断和治疗的知识,重点介绍磺胺过敏患者的替代治疗方法。材料和方法:使用弓形虫、眼弓形虫病、后葡萄膜炎和视网膜脉络膜炎等术语进行了全面的PubMed检索(1908-2021)。优先考虑2000年以后发表的研究,特别是2010年以后发表的研究。谷歌学者,以及英语和西班牙语的来源,也被利用。结果:眼弓形虫病是世界范围内最常见的后葡萄膜炎感染形式,典型表现为坏死性视网膜脉络膜炎伴玻璃体黄斑粘连和玻璃体炎。诊断以临床为主,必要时可通过血清学(IgG/IgM)和眼内液PCR进行支持。标准治疗包括全身抗寄生虫药物(例如,乙胺嘧啶与磺胺嘧啶或甲氧苄氨嘧啶-磺胺甲恶唑)加皮质类固醇。对于磺胺过敏的患者,乙胺嘧啶联合克林霉素或阿奇霉素,或玻璃体内克林霉素联合地塞米松是有效的。最近的研究表明,这些方案的效果相当。及时治疗活动性疾病有助于减少视网膜损伤。讨论:最近的证据支持非磺胺方案和玻璃体内治疗治疗眼弓形虫病的有效性和安全性。这些选择对有标准治疗禁忌症的患者特别有价值。成像和分子诊断技术的进步也提高了对该病的早期识别和针对性治疗,有助于改善视力。结论:诊断工具(PCR、眼内抗体检测)和替代疗法的进步改善了眼弓形虫病的预后,包括对磺胺不耐受的患者。克林霉素或玻璃体内入路是有效、安全的选择。需要进一步的研究来完善治疗方案,防止复发,并阐明疾病的发病机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Sulfonamide Allergy and Alternative Treatments in Ocular Toxoplasmosis.

Purpose: To summarize current knowledge on the clinical features, diagnosis, and treatment of ocular toxoplasmosis, with emphasis on alternatives for sulfonamide-allergic patients.

Materials and methods: A comprehensive PubMed search (1908-2021) was conducted using terms like Toxoplasma gondii, ocular toxoplasmosis, posterior uveitis, and retinochoroiditis. Priority was given to studies published after 2000, particularly those from 2010 onwards. Google Scholar, as well as English and Spanish sources, were also utilized.

Results: Ocular toxoplasmosis is the most common infectious form of posterior uveitis worldwide, typically presenting as necrotizing retinochoroiditis with associated vitreomacular adhesion and vitritis. Diagnosis is mainly clinical, supported by serology (IgG/IgM) and PCR of intraocular fluids when needed. Standard treatment includes systemic antiparasitic agents (e.g., pyrimethamine with sulfadiazine or trimethoprim-sulfamethoxazole) plus corticosteroids. In patients with sulfonamide allergies, alternatives such as pyrimethamine with clindamycin or azithromycin, or intravitreal clindamycin with dexamethasone, are effective. Recent studies show comparable outcomes with these regimens. Prompt treatment of active disease helps reduce retinal damage.

Discussion: Recent evidence supports the efficacy and safety of non-sulfonamide regimens and intravitreal therapies in managing ocular toxoplasmosis. These options are particularly valuable for patients with contraindications to standard treatments. Advances in imaging and molecular diagnostics have also enhanced early recognition and tailored management of the disease, contributing to improved visual outcomes.

Conclusion: Advances in diagnostic tools (PCR, intraocular antibody detection) and alternative therapies have improved outcomes in ocular toxoplasmosis, including in patients who are intolerant to sulfonamides. Clindamycin-based or intravitreal approaches offer effective, safe options. Further research is needed to refine treatment protocols, prevent recurrences, and clarify disease pathogenesis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信